CHRNB3 Antibody
Description
Definition and Target
CHRNB3 antibodies are designed to bind specifically to the β3 subunit of nAChRs. This subunit is part of heteropentameric receptor complexes that mediate acetylcholine signaling. The antibody’s role includes detecting CHRNB3 expression in tissues, studying receptor localization, and investigating its involvement in diseases like nicotine dependence and neurodegenerative disorders .
Types of CHRNB3 Antibodies
CHRNB3 antibodies vary in host species, clonality, and epitope specificity. Key categories include:
Epitope Specificity and Antibody Design
The epitope region targeted significantly influences antibody specificity and utility:
-
Middle Region (AA 67–218): Broad reactivity across species (human, mouse, rat, dog) and applications (WB, ELISA, IHC) .
-
AA 187–200: Hamster-specific reactivity, validated for Western blotting .
-
Extracellular Domains (AA 211–222): Rat-specific, used for live cell imaging and surface detection in PC12 cells .
-
AA 50–250: Human-specific, optimized for immunohistochemistry (IHC-P) and immunocytochemistry (ICC/IF) .
Applications in Research
CHRNB3 antibodies enable diverse experimental approaches:
Western Blotting
-
Detection of CHRNB3 in brain membranes (e.g., rat brain lysates) .
-
Validation of recombinant CHRNB3 proteins (e.g., HEK293-expressed fragments) .
Immunohistochemistry (IHC)
-
Localization in human lung and endometrial cancer tissues, highlighting CHRNB3’s role in tumorigenesis .
-
Surface staining in live PC12 cells using extracellular-specific antibodies .
ELISA and Functional Studies
Genetic and Functional Studies
-
Investigating CHRNB3’s role in nicotine dependence: Antibodies are used to study receptor expression in brain regions linked to addiction (e.g., ventral tegmental area) .
-
Analyzing receptor subunit interactions: CHRNB3’s association with α6 subunits in dopaminergic signaling .
Nicotine Dependence
-
Genetic associations: Variants in the CHRNB3–CHRNA6 gene cluster correlate with nicotine dependence severity and withdrawal symptoms .
-
Functional studies: Antibodies validate α6/β3 nAChR involvement in dopamine release and nicotine-induced reward .
Cancer Research
-
CHRNB3 expression in lung and endometrial cancers is detected via IHC, suggesting potential therapeutic targets .
Neurological Disorders
-
Dystonia and emphysema: CHRNB3 mutations are linked to these conditions, with antibodies aiding in mechanistic studies .
Technical Considerations
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- To further comprehend the pathological processes underlying nicotine dependence and related behaviors, and to foster the development of effective smoking cessation therapies, we present the latest research focusing on the genetic effects of the CHRNB3-CHRNA6 gene cluster in nicotine dependence. PMID: 27327258
- Studies have observed a higher prevalence of low frequency variants within the CHRNA6/CHRNB3 gene region among individuals with nicotine dependence compared to control groups. PMID: 27085880
- Research provides evidence that the protective genetic variant at rs6474413, identified in human genetic studies, reduces gene expression. Furthermore, decreased beta3 gene expression in mice has been shown to lower nicotine intake. PMID: 26318101
- A patient's chromosomal abnormality was found to affect only one gene, which is highly expressed in the brainstem and brain, involved in neurotransmission, and potentially related to her Duane retraction syndrome. PMID: 24001015
- The CHRNB3-A6 locus harbors multiple variants influencing susceptibility to cocaine and nicotine dependence, as well as bipolar disorder, suggesting their pleiotropic effects. PMID: 24675634
- Polymorphism within the CHRNB3 gene has been linked to esophageal adenocarcinoma. PMID: 25823894
- The common variant rs13273442 in the CHRNB3-CHNRA6 region demonstrates a significant association with nicotine dependence among both European Americans and African Americans. PMID: 24401102
- The CHRNB3 c.-57A>G alteration influences promoter activity and is associated with Parkinson's disease (PD) and smoking behavior in PD patients. PMID: 24731518
- This study provides compelling evidence for a role of CHRNB3 in nicotine dependence. PMID: 23319001
- These findings indicate that the combined effect of rs6474412-C/T polymorphism in the smoking-related CHRNB3-CHRNA6 gene region and smoking behavior may not contribute to the risk of psoriasis vulgaris (PV), but may influence PV severity in the Chinese Han population. PMID: 24792900
- Results demonstrate an association between SNPs in CHRNB3 nicotinic acetylcholine receptor genes and the risk of smoking in individuals with attention-deficit/hyperactivity disorder (ADHD). PMID: 23899432
- The results strongly suggest that the genetic locus for the CHRNB3 gene is significantly associated with nicotine dependence. PMID: 22524403
- Coexpression of the beta3 subunit enhances the function of alpha6*-nAChR. PMID: 22315221
- Variants within CHRNB3/CHRNA6 are independently associated with bipolar disorder. PMID: 21191315
- The GG genotype of SNP rs13261190 in CHRNB3 was linked to increased novelty seeking in individuals with alcohol dependence. PMID: 21606657
- CHRNB3 and CHRNA6 polymorphisms are associated with smoking behavior and lung cancer susceptibility in the Chinese Han population. PMID: 21831805
- Three single nucleotide polymorphisms (SNPs) in CHRNA6 and one SNP in CHRNB3 have been associated with a composite of alcohol phenotypes. PMID: 19500157
- CHRNB3-CHRNA6 and CYP2A6 sequence variants influence smoking behavior. PMID: 20418888
- CHRNB3 is associated with subjective responses to tobacco. PMID: 18055561
- These results further implicate the region downstream of CHRNA6 and the region upstream of CHRNB3 in the risk of nicotine dependence. PMID: 18704094
